
    
      This will be a Phase 1, open-label, 2-period, 2-treatment, fixed-sequence, cross-over study
      in approximately 12 healthy subjects employing administration of a single oral dose of
      PF-06463922 in the fasted state alone, and with multiple dosing of rifampin 600 mg once a day
      to estimate the effect of multiple dose rifampin on the single dose PK of PF-06463922.
    
  